BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang XX, Li MR, Xi HL, Cao Y, Zhang RW, Zhang Y, Xu XY. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy. Chin Med J (Engl). 2016;129:929-935. [PMID: 27064037 DOI: 10.4103/0366-6999.179802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol 2018; 24(6): 725-736 [PMID: 29456411 DOI: 10.3748/wjg.v24.i6.725] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Xie YD, Ma H, Feng B, Wei L. Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. Chin Med J (Engl) 2017;130:2190-7. [PMID: 28875955 DOI: 10.4103/0366-6999.213969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Chin Med J (Engl) 2017;130:559-65. [PMID: 28229987 DOI: 10.4103/0366-6999.200554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]